Clinical Trial Update: RAD001 Plus Bevacizumab in Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating RAD001 ( everolimus ) plus bevacizumab in metastatic melanoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• RAD001 (everolimus)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Metastatic Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2013-02-26